PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
PTC Therapeutics confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington’s disease at study sites globally. To date, PTC has received approval for conduct of the planned 12-month study in several European countries as well as Australia.
